DyeVert Plus EZ System

Preventing Contrast-Induced Acute Kidney Injury (AKI) in Your Cath Lab Patients

The DyeVert Plus EZ System is a simple, easy to use solution to prevent AKI in patients with Chronic Kidney Disease (CKD) and high risk co-morbidities.1-8

Quote from Briguori, et al.
  • > 50% mean relative AKI reduction in real-world and comparative studies
  • Consistently reduces contrast delivered to patients on average 40%9,10
  • Integrates seamlessly into coronary and peripheral angiography procedures

Proven Reduction in AKI

Real-world results: 55% mean relative AKI reduction1-4

Cath Lab quality improvement (QI) programs to reduce AKI demonstrated a 55% mean relative AKI reduction with the DyeVert System.

QI Programs AKI Reduction

QI Programs AKI Reduction

Comparative results: 51% mean relative AKI reduction5-8

Studies comparing AKI rates in patients treated with and without the DyeVert System demonstrated a 51% mean relative AKI reduction in patients treated with DyeVert.

Control vs. DyeVert System AKI Reduction

Control vs. DyeVert System AKI Reduction

AKI Increases Hospital Costs

AKI dramatically increases costs for hospitals – upwards of $15,000 per AKI event – due to increased length of stay and 30-day readmissions.12

Preventing AKI with the DyeVert System in high-risk patients can offer cost savings of up to $2,000 per patient.*

AKI Increases Hospital Costs

AKI Burden of Illness Study – Premier Healthcare Database
A study of 749 hospitals with 2.8M coronary angiography patients11

Learn more
The DyeVert System Impact
Contact us

*Data on file

References
1. Castro D, Dang TT. Reducing contrast-induced acute kidney injury in the cath lab. Poster presentation at ACC National Cardiovascular Data Registry (NCDR) 2018 Annual Conference.
2. Thukral N. Kidney care protocols in the cath lab. Transcatheter Cardiovascular Therapeutics 2019 Presentation. Accessed on October 14, 2019 from: https://www.tctmd.com/slide/aki-reduction-cath-lab-protocol-development-implementation-and-outcomes.
3. Turner C, Tucker PA. Real-world impact of a quality improvement program for AKI prevention in the cardiac cath lab. SCAI Scientific Sessions Virtual Conference. Catheter & Cardiovasc Interv. 2020;95 (Supplement 2): S112-S113.
4. Cameron A, Espinosa TJ. Reducing contrast-induced acute kidney injury in a cardiac catherization laboratory: a quality improvement initiative. SCAIScientificSessionsVirtualConference. Catheter&CardiovascInterv. 2020;95(Supplement 2):S25.
5. Bunney R, Saenger E, Shah C, et al. Contemporary use of contrast dye reduction technology in a tertiary academic hospital: patient characteristics and acute kidney injury outcomes following percutaneous coronary interventions. Poster presented at ACC Quality Summit 2019; Poster 2018-063.
6. Kutschman R. Clinical and economic outcomes of a comprehensive clinical quality initiative for reducing acute kidney injury in chronic kidney disease patients undergoing coronary angiography. JACC. 2019;74 (13 Suppl): B605.
7. Sattar A, et al. Impact of using DyeVert Plus on incidence of acute kidney injury after cardiac catheterizations with coronary interventions in high risk patients. ACC Annual Meeting 2018; Charleston, WV.
8. Briguori C, Golino M, Porchetta N, et al. Impact of a contrast media volume control device on acute kidney injury rate in patients with acute coronary syndrome. Catheter & Cardiovasc Interv. 2020 Jul 18. doi: 10.1002/ccd.29136.
9. Desch S, et al. Impact of a novel contrast reduction system on contrast savings in coronary angiography – The DyeVert randomized controlled trial. Int J of Cardiol. 2018;(257):50-53.
10. Gurm H, et al. Minimizing radiographic contrast administration during coronary angiography using a novel contrast reduction system: A multicenter observational study of the DyeVert Plus contrast reduction system. Catheter & Cardiovasc Interv 2019;93(7):1228-35.
11. Prasad A, et al. Contemporary trend of acute kidney injury incidence and incremental costs among US patients undergoing percutaneous coronary procedures. Catheter Cardiovasc Interv. 2020 Nov;96(6):1184-1197.

DyeVert, Osprey Medical, and Be Kind to Kidneys are trademarks of Osprey Medical, Inc. in the US and other countries.
©2021 Osprey Medical, Inc. All Rights Reserved.

Please consult labels and package inserts for indication, contraindications, warnings, precautions, complications, and information for use.
CAUTION: Federal (USA) law restricts these devices to sale by or on order of a physician.

Osprey Medical
Be Kind to Kidneys Logo